<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140528</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Bone-012</org_study_id>
    <nct_id>NCT02140528</nct_id>
  </id_info>
  <brief_title>Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures</brief_title>
  <official_title>Evaluation the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a case-control prospective, clinal trial to assess the safety and efficacy of
      the allogeneic adipose derived mesenchymal stem cell transplantation on the healing of recent
      tibial fracture in 40 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study all eligible patients divided in 2 group.20 patients received allogeneic
      adipose derived mesenchymal stem cell in the fractured site (case group) and other patients
      received the placebo in the fractured site (control group) .

      To assess the outcomes, we will evaluate the patients at 2, 6 weeks and 3, 6 months after
      transplantation by: X-ray, BMD , VAS and biochemical analysis with laboratory tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with union after transplantation of mesenchymal stem cell in case group in comparison with control group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Tibial Fracture</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell receipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection in the site of fracture in patients with tibia fracture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cell injection</intervention_name>
    <description>Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .</description>
    <arm_group_label>Mesenchymal stem cell receipients</arm_group_label>
    <other_name>stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  The presence of tibial fracture based on X ray

          -  tibial fracture is limited to diaphysial

        Exclusion Criteria:

          -  Addiction

          -  Pregnancy

          -  liver or kidney disease or uncontrolled diabetes or heart and lung disease

          -  immune deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of regenerative medicine department &amp;cell therapy center of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohsen Emaddedin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department or regenerative medicine of Royan Institute.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aziz Ahmadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific board of Iranian Orthopedic Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maedeh Ghorbani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Regenerative Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Afshin Farhadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific board of Iranian Orthopedic Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogenic adipose derived mesenchymal stem cell tibial fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

